Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects
Lukas Kraehenbuehl1, Jedd D Wolchok2, Taha Merghoub3
1Pharmacology Program, Weill Cornell Graduate School, New York, NY, USA; Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medical Center, New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medical Center, New York, NY, USA; Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
The antimicrobial drug clofazimine enhances cancer immunotherapy effectiveness while reducing harmful side effects. This discovery offers a promising strategy for improving combined immune checkpoint blockade (ICB) treatments.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Combined immune checkpoint blockade (ICB) shows efficacy in some cancer patients.
- ICB treatment is associated with immune-related adverse events.
- Novel strategies are needed to improve ICB efficacy and safety.
Purpose of the Study:
- To identify agents that can potentiate ICB efficacy.
- To find drugs that mitigate ICB-associated immune-related adverse events.
Main Methods:
- Utilized a drug screening strategy.
- Investigated the effects of identified compounds on ICB.
- Evaluated the impact on both efficacy and adverse events.
Main Results:
- Identified the antimicrobial drug clofazimine.
- Clofazimine was found to potentiate ICB efficacy.
- Clofazimine also decreased immune-related adverse events.
Conclusions:
- Clofazimine is a potential therapeutic agent for improving combined immune checkpoint blockade.
- This finding offers a dual benefit of enhanced efficacy and reduced toxicity for cancer immunotherapy.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combined Effects of Drugs: Synergism
Such synergistic combinations...


